Trial of Ibudilast for Methamphetamine Dependence

Summary

The objective of this study is to test the safety and potential efficacy of ibudilast to treat methamphetamine dependence. The study hypotheses are that ibudilast will reduce methamphetamine use and increase treatment retention more than placebo among patients seeking treatment for methamphetamine dependence. As HIV infection is a common complication of methamphetamine dependence, half of the participants will be HIV positive and the study will assess whether ibudilast also improves HIV related outcomes (e.g. medication adherence, CD4 count, risk behaviors).

Timeline

Start

2013-07

Primary completion

2017-12-31

Completion

2017-12-31

Outcome

Missed primary endpoint

release “Phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence, which was recently completed by investigators at UCLA, did not meet the primary endpoint” medicinova.com ↗

Drugs

Indications